Cargando…
Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
Autores principales: | Mahdian, Soodeh, Zarrabi, Mahboobeh, Panahi, Yunes, Dabbagh Sadeghpour, Somayyeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158040/ https://www.ncbi.nlm.nih.gov/pubmed/37362152 http://dx.doi.org/10.1016/j.imu.2023.101263 |
Ejemplares similares
-
Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations
por: Mahdian, Soodeh, et al.
Publicado: (2021) -
Effectiveness of Remdesivir in Comparison with Five Approved Antiviral Drugs for Inhibition of RdRp in Combat with SARS-CoV-2
por: Mahdian, Soodeh, et al.
Publicado: (2022) -
Inhibition of HEV Replication by FDA-Approved RdRp
Inhibitors
por: Hooda, Preeti, et al.
Publicado: (2023) -
RdRp or RT, That is the Question
por: Peyambari, Mahtab, et al.
Publicado: (2021) -
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
por: Molavi, Zahra, et al.
Publicado: (2021)